Findings

What do systematic reviews say?

8 questions · 8 findings · 5 reviews · Schizophrenia

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 3 · 37.5%Low 3 · 37.5%Moderate 2 · 25%High 0 · 0%

H2 receptor antagonists vs placebo

Leaving the study early · people with schizophrenia with antipsychotic‐induced weight gain

H2 antagonists showed no clear difference in leaving the study early: for any reason compared with placebo (low certainty).

1 finding from 1 review

Pharmacological interventions for prevention of weight gain in people with schizophrenia 2022 · Cochrane Headline outcomes only
RR 1.07 [0.72, 1.57]
2 studies · 189 participants
Low

Monoamine modulators vs placebo

Leaving the study early · people with schizophrenia with antipsychotic‐induced weight gain

Monoamine modulators showed no clear difference in leaving the study early: for any reason compared with placebo (low certainty).

1 finding from 1 review

Pharmacological interventions for prevention of weight gain in people with schizophrenia 2022 · Cochrane Headline outcomes only
RR 1.05 [0.56, 1.94]
3 studies · 115 participants
Low

Topiramate vs placebo or no treatment

Leaving the study early · people with schizophrenia with antipsychotic‐induced weight gain

Topiramate showed no clear difference in leaving the study early: for any reason compared with placebo or no treatment (low certainty).

1 finding from 1 review

Pharmacological interventions for prevention of weight gain in people with schizophrenia 2022 · Cochrane Headline outcomes only
RR 1.09 [0.85, 1.41]
2 studies · 132 participants
Low

Metformin vs placebo or no treatment

Leaving the study early · people with schizophrenia with antipsychotic‐induced weight gain

It is very uncertain whether metformin changes leaving the study early: for any reason compared with placebo or no treatment (very low certainty).

1 finding from 1 review

Pharmacological interventions for prevention of weight gain in people with schizophrenia 2022 · Cochrane Headline outcomes only
RR 1.02 [0.25, 4.13]
4 studies · 137 participants
Very low

Mirtazapine adjunct vs placebo adjunct

Leaving the study early · schizophrenia

Mirtazapine adjunct showed no clear difference in leaving the study early for any reason compared with placebo adjunct (moderate certainty).

1 finding from 1 review

Mirtazapine adjunct for people with schizophrenia 2018 · Cochrane Headline outcomes only
RR 1.03 [0.64, 1.66]
9 studies · 310 participants
Moderate

Modafinil vs placebo

Leaving the study early · schizophrenia or related disorders

Modafinil showed no clear difference in leaving the study early ‐ for any reason compared with placebo (moderate certainty).

1 finding from 1 review

Modafinil for people with schizophrenia or related disorders 2019 · Cochrane Headline outcomes only
RR 1.26 [0.63, 2.53]
9 studies · 357 participants
Moderate

Aspirin plus antipsychotics vs placebo/no adjunctive treatment + antipsychotics

Behaviour: Leaving the study early (short‐term) · patients with schizophrenia

It is very uncertain whether aspirin plus antipsychotics changes leaving the study early: short‐term – for any reason compared with placebo plus antipsychotics (very low certainty).

1 finding from 1 review

Acetylsalicylic acid (aspirin) for schizophrenia 2019 · Cochrane Headline outcomes only
RR 1.12 [0.4, 3.14]
2 studies · 130 participants
Very low

VALPROATE + ANTIPSYCHOTICS vs placebo/no adjunctive treatment + antipsychotics

Acceptability of treatment ‐ leaving the study early · patients with schizophrenia

It is very uncertain whether VALPROATE + ANTIPSYCHOTICS changes leaving the study early: Acceptability of treatment Leaving the… compared with ANTIPSYCHOTICS + PLACEBO or ANTIPSYCHOTICS alone (very low certainty).

1 finding from 1 review

Valproate for schizophrenia 2016 · Cochrane Headline outcomes only
RR 0.76 [0.47, 1.24]
11 studies · 951 participants
Very low